Drug Search Results
More Filters [+]

CGC-11047

Alternative Names: cgc-11047, cgc11047, cgc 11047
Latest Update: 2016-07-21
Latest Update Note: Clinical Trial Update

Product Description

Progen was developing cgc-11047, an intravenous DNA synthesis inhibitor, for the treatment of CNV from Age Related Macular Degeneration (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00446654)

Mechanisms of Action: DNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Progen
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CGC-11047

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Prostate Cancer

Phase 1: Lymphoma|Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00705874

P1

Completed

Lymphoma

2011-08-01

HSC2006-0099

P2

Terminated

Prostate Cancer

2007-11-01

47-MD-002

P1

Completed

Macular Degeneration

2007-10-01

Recent News Events

Date

Type

Title